OMER Omeros Corporation Stock Quote

OMER [NASD]

Index	-	P/E	-	EPS (ttm)	-2.38	Insider Own	0.50%	Shs Outstand	58.23M	Perf Week	-8.89%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-1.93	Insider Trans	-10.39%	Shs Float	54.75M	Perf Month	3.70%
Income	-130.00M	PEG	-	EPS next Q	-0.64	Inst Own	56.40%	Short Float	23.31%	Perf Quarter	71.89%
Sales	96.60M	P/S	12.43	EPS this Y	34.60%	Inst Trans	-1.80%	Short Ratio	14.05	Perf Half Y	67.47%
Book/sh	-1.50	P/B	-	EPS next Y	20.70%	ROA	-94.10%	Target Price	33.14	Perf Year	60.29%
Cash/sh	2.58	P/C	7.82	EPS next 5Y	-	ROE	106.20%	52W Range	8.50 - 25.46	Perf YTD	41.27%
Dividend	-	P/FCF	-	EPS past 5Y	5.10%	ROI	-121.90%	52W High	-20.74%	Beta	1.41
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	190.70%	Gross Margin	98.70%	52W Low	137.41%	ATR	1.32
Employees	258	Current Ratio	4.10	Sales Q/Q	-12.70%	Oper. Margin	-	RSI (14)	48.52	Volatility	9.92% 5.93%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-98.10%	Profit Margin	-	Rel Volume	1.31	Prev Close	19.41
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 01 AMC	Payout	-	Avg Volume	908.11K	Price	20.18
Recom	2.10	SMA20	-6.28%	SMA50	8.76%	SMA200	40.86%	Volume	1,192,680	Change	3.97%

Feb-01-21

Initiated

UBS

Buy

$25

Oct-20-20

Initiated

BofA Securities

Buy

$21

Aug-21-20

Reiterated

H.C. Wainwright

Buy

$34 → $32

Aug-14-20

Reiterated

Maxim Group

Buy

$25 → $20

May-06-19

Initiated

Cantor Fitzgerald

Overweight

$26

Jul-12-18

Initiated

Seaport Global Securities

Buy

$30

Mar-23-18

Downgrade

Wedbush

Outperform → Neutral

$47 → $19

Mar-05-18

Downgrade

Needham

Buy → Hold

Nov-08-17

Initiated

H.C. Wainwright

Buy

$30

May-11-17

Downgrade

Cantor Fitzgerald

Buy → Neutral

$21 → $15

Mar-17-17

Reiterated

Needham

Buy

$24 → $22

Mar-17-17

Reiterated

Maxim Group

Buy

$19 → $22

Nov-16-16

Reiterated

Wedbush

Outperform

$56 → $47

Nov-10-16

Reiterated

Needham

Buy

$28 → $24

Aug-10-16

Reiterated

Maxim Group

Buy

$30 → $19

Jun-03-16

Initiated

Cantor Fitzgerald

Buy

$21

Mar-02-16

Reiterated

Needham

Buy

$30 → $28

Feb-29-16

Reiterated

Wedbush

Outperform

$65 → $62

Nov-11-15

Reiterated

Needham

Buy

$32 → $30

Aug-18-15

Reiterated

WBB Securities

Strong Buy

$60 → $75

Mar-01-21 05:25PM	Omeros (OMER) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:18PM	Recap: Omeros Q4 Earnings Benzinga
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results Business Wire
02:30PM	Omeros Corp. to Host Earnings Call ACCESSWIRE
Feb-25-21 09:37AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021 Business Wire -14.45%
Feb-03-21 05:30AM	How Many Omeros Corporation (NASDAQ:OMER) Shares Do Institutions Own? Simply Wall St.
Jan-26-21 08:45AM	Omeros Hires Nadia Dac as Chief Commercial Officer Business Wire
Jan-19-21 08:30AM	Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA Business Wire +7.75%
Jan-11-21 04:30PM	Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-20 11:42PM	Is OMER A Good Stock To Buy Now? Insider Monkey
Dec-05-20 02:43AM	Analysts Just Published A Bright New Outlook For Omeros Corporation's (NASDAQ:OMER) Simply Wall St.
Dec-03-20 07:30AM	CMS Confirms Continued Separate Payment for Omeros FDA-Approved OMIDRIA® in Ambulatory Surgery Centers Business Wire +14.72%
Dec-02-20 08:57AM	Omeros (OMER) in Focus: Stock Moves 8.5% Higher Zacks
Nov-18-20 09:00AM	Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA Business Wire
Nov-12-20 09:54AM	Looking Into Omeros's Return On Capital Employed Benzinga
Nov-09-20 05:45PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.27%
04:46PM	Omeros: Q3 Earnings Insights Benzinga
04:02PM	Omeros Corporation Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	Omeros Corp. to Host Earnings Call ACCESSWIRE
Nov-05-20 07:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020 Business Wire
Nov-03-20 12:31PM	Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-20 09:00AM	Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development Business Wire
Oct-22-20 08:00AM	Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA Business Wire
Oct-20-20 09:56AM	Benzinga's Top Upgrades, Downgrades For October 20, 2020 Benzinga
Oct-16-20 08:30AM	Omeros OMS906 Data Presented at Complement-based Drug Development Summit Business Wire
Oct-15-20 08:00AM	Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA Business Wire +6.51%
Oct-01-20 09:00AM	Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs Business Wire
Sep-14-20 02:10PM	Key Things To Understand About Omeros' (NASDAQ:OMER) CEO Pay Cheque Simply Wall St. +5.60%
Sep-11-20 07:00AM	Omeros to Present at the Cantor Virtual Global Healthcare Conference Business Wire
Sep-09-20 08:45AM	Omeros (OMER) Catches Eye: Stock Jumps 6% Zacks
Sep-03-20 09:38AM	Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients Business Wire
Aug-31-20 08:18AM	How Does Omeros's Debt Look? Benzinga
08:00AM	Omeros Investigational New Drug Application for OMS906 Cleared by FDA Business Wire
Aug-12-20 12:35PM	Here's Why Omeros Fell Over 13% Today Motley Fool -13.97%
06:30AM	Omeros Announces Pricing of Public Offerings Business Wire
Aug-11-20 08:20AM	The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September Benzinga -25.47%
Aug-10-20 05:45PM	Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates Zacks +50.88%
04:12PM	Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes Business Wire
04:01PM	Omeros Corporation Reports Second Quarter 2020 Financial Results Business Wire
12:25PM	Dow Jones Leads, Nasdaq Lags As Market Weighs Trump Orders, China Tensions Investor's Business Daily
11:41AM	Omeros Rallies On COVID-19 Study Results: What You Should Know Benzinga
11:35AM	ROCE Insights For Omeros Benzinga
09:01AM	Omeros Reports Coronavirus Treatment Success; Stock Soars Investor's Business Daily
07:30AM	Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome Business Wire
Aug-06-20 12:30PM	Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-20 06:27AM	Could This Obscure Biotech Stock Make You a Fortune? Motley Fool
Jul-15-20 03:06PM	Omeros'(NASDAQ:OMER) Share Price Is Down 35% Over The Past Three Years. Simply Wall St. +5.62%
Jun-24-20 04:27PM	Hedge Funds Are Buying Omeros Corporation (OMER) Insider Monkey
Jun-12-20 08:30AM	Omeros Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress Business Wire
Jun-11-20 08:45AM	Omeros Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress Business Wire
Jun-08-20 02:28PM	Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents +6.28%
May-26-20 06:45PM	Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75 Investor's Business Daily
May-14-20 09:00AM	Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress Business Wire
May-12-20 06:01AM	Omeros (OMER) Q1 2020 Earnings Call Transcript Motley Fool -11.60%
May-11-20 06:55PM	Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks +6.15%
04:02PM	Omeros Corporation Reports First Quarter 2020 Financial Results Business Wire
May-08-20 08:36AM	Should You Buy Omeros (OMER) Ahead of Earnings? Zacks
May-05-20 07:00AM	Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020 Business Wire
Mar-11-20 03:38PM	Edited Transcript of OMER earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents -8.74%
Mar-04-20 10:00AM	Company News for Mar 4, 2020 Zacks
Mar-02-20 05:35PM	Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates Zacks +5.71%
04:03PM	Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results Business Wire
04:01PM	Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA Business Wire
Feb-24-20 07:00AM	Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020 Business Wire
Feb-11-20 09:35AM	Is Omeros Corporation's (NASDAQ:OMER) CEO Salary Justified? Simply Wall St.
08:30AM	Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors Business Wire
Feb-03-20 03:49PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Jan-23-20 05:30PM	Omeros seeks accelerated approval from FDA for new drug American City Business Journals
Dec-20-19 05:16PM	Hedge Funds Arent Crazy About Omeros Corporation (OMER) Anymore Insider Monkey
Dec-18-19 08:30AM	myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab Business Wire
Dec-16-19 08:30AM	Omeros Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors Business Wire
Dec-13-19 09:30AM	Omeros Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares Business Wire
Dec-10-19 08:30AM	Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva Business Wire
Dec-05-19 07:14AM	The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga -12.66%
Dec-04-19 04:11PM	Omeros Announces Proposed Public Offering of Common Stock Business Wire +6.05%
10:42AM	Omeros Aces Late-Stage Trial Of Transplant Drug Narsoplimab Benzinga
10:38AM	Omeros stock gains on transplant drug data MarketWatch
07:00AM	Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab Business Wire
Dec-03-19 11:45PM	Edited Transcript of OMER earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 08:45AM	Omeros New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online Business Wire
Nov-19-19 08:45AM	Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston Business Wire
Nov-16-19 08:10AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
Nov-13-19 02:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
09:59AM	What Kind Of Shareholder Appears On The Omeros Corporation's (NASDAQ:OMER) Shareholder Register? Simply Wall St.
Nov-12-19 05:35PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM	Omeros Corporation Reports Third Quarter 2019 Financial Results Business Wire
Nov-11-19 05:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
Nov-08-19 08:30AM	Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy Business Wire
Nov-07-19 05:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER ACCESSWIRE
08:30AM	Omeros Scientists Win 2019 Prix Galien Research Award Business Wire
Nov-06-19 08:15AM	Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
Nov-04-19 03:00PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Omeros Corporation (OMER) ACCESSWIRE -16.10%
02:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER GlobeNewswire
07:50AM	Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain Business Wire
Nov-01-19 11:22AM	Were Hedge Funds Right About Warming Up To Omeros Corporation (OMER)? Insider Monkey
Oct-29-19 09:00AM	Omeros Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission Business Wire
Oct-28-19 08:45AM	Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA Business Wire +6.15%
Oct-21-19 09:46AM	Here's Why You Should Hold on to Chemed (CHE) Stock Right Now Zacks
Oct-18-19 04:31AM	2 Candidates That Could Be the Next Biotech Rockets TheStreet.com
Oct-01-19 08:30AM	Product-Specific J-Code for Omeros OMIDRIA® is Now in Effect Business Wire

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 22	Option Exercise	10.27	8,100	83,187	22,100	Feb 23 05:20 PM
Demopulos Peter A MD	Director	Feb 22	Option Exercise	4.92	10,000	49,150	198,516	Feb 23 06:43 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 22	Sale	23.28	8,100	188,568	14,000	Feb 23 05:20 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 19	Option Exercise	10.27	10,000	102,700	24,000	Feb 23 05:20 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 19	Sale	22.64	10,000	226,400	14,000	Feb 23 05:20 PM
Hood Leroy E. MD PhD	Director	Feb 12	Option Exercise	4.53	5,000	22,650	74,390	Feb 17 05:15 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 10	Option Exercise	10.27	1,900	19,513	15,900	Feb 12 05:05 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Feb 10	Sale	22.49	1,900	42,731	14,000	Feb 12 05:05 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Jan 20	Option Exercise	9.37	10,000	93,700	14,000	Jan 21 05:15 PM
JACOBSEN MICHAEL A	VP FINANCE AND CAO	Jan 19	Sale	19.95	9,500	189,525	4,000	Jan 21 05:15 PM
Cable Thomas J.	Director	Jan 13	Option Exercise	4.53	5,000	22,650	40,067	Jan 15 05:15 PM
Cable Thomas J.	Director	Jan 13	Sale	16.97	5,000	84,850	35,067	Jan 15 05:15 PM
Cable Thomas J.	Director	May 13	Option Exercise	5.92	5,000	29,600	40,067	May 15 08:00 PM
Cable Thomas J.	Director	May 13	Sale	14.40	5,000	71,999	35,067	May 15 08:00 PM
Hood Leroy E. MD PhD	Director	Mar 13	Option Exercise	5.92	5,000	29,600	69,390	Mar 17 05:25 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience